Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
ConclusionAccording to the results, it is recommended that health policymakers consider the use of valsartan by cardiologists when designing clinical guidelines for the treatment of patients with heart failure.
Source: Health Economics Review - Category: International Medicine & Public Health Source Type: research
More News: Cardiology | Cardiovascular | Diovan | Disability | Economics | Enalapril | Heart | Heart Failure | Intensive Care | International Medicine & Public Health | Iran Health | Middle East Health | Study